Experimental protein therapy targets rare brain disease

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Age between 30 and 75 years inclusive, either sex; * 2\. Clinically established or clinically probable MSA (including both MSA-C and MSA-P subtypes); * 3\. Ability to walk independently or with the aid of a walking device for at least 10 meters; * 4\. Provision of written informed consent. Exclusion Criteria: * 1\. Evidence of other central nervous system pathologies on brain MRI at screening suggesting a diagnosis of neurodegenerative diseases other than MSA; * 2\. Other significant pathological findings on brain MRI at screening, including but not limited to: cerebral hemorrhage, acute cerebral infarction, aneurysm, vascular malformation, infectious lesions, brain tumors, or other space-occupying lesions (meningiomas or arachnoid cysts with a maximum diameter \<1 cm do not require exclusion); * 3\. Presence of immune-mediated diseases that are inadequately controlled or require treatment with biologic agents; * 4\. Known history of allergies to biologic agents, such as proteins or cell-based products; * 5\. Receipt of any vaccination within the past 1 month; * 6\. Patients with a prior definitive diagnosis of malignancy or those currently receiving anti-tumor drug therapy; * 7\. Patients with a prior definitive diagnosis of epilepsy or those currently taking anti-epileptic drugs; * 8\. Concurrent severe hepatic insufficiency, renal insufficiency, or severe cardiac insufficiency (severe hepatic insufficiency defined as ALT ≥1.5 times the upper limit of normal or AST ≥1.5 times the upper limit of normal; severe renal insufficiency defined as serum creatinine \[CRE\] ≥1.5 times the upper limit of normal or estimated glomerular filtration rate \[eGFR\] \<40 mL/min/1.73 m²; severe cardiac insufficiency defined as NYHA class 3-4), or any significant abnormalities on physical examination, vital signs, laboratory tests, or electrocardiogram that, in the investigator's opinion, require further examination or treatment, or may interfere with the study procedures or safety; * 9\. Patients with a history of alcohol or substance abuse, or alcohol or substance dependence within the past 2 years; * 10\. Patients diagnosed with psychiatric disorders according to DSM-V criteria, or those with obvious suicidal intent; * 11\. Patients who are pregnant, lactating, or have the potential to become pregnant, or those planning a pregnancy; * 12\. Inability to comply with follow-up assessments due to other reasons; * 13\. Patients deemed by the investigator to be unsuitable for participation in this study.